Payment overview · 2025
General Payments
$367.85
20 reported records · 5 companies
Healthcare provider profile · identity verified
Jackie S Miller, DO
Allopathic & Osteopathic Physicians|Family Medicine · ALBANY, MO · NPI 1053353045
Verified facts
What the public records show
CMS Open Payments records show Jackie S Miller, DO received $367.85 in general payments during 2025 across 20 reported records.
ABBVIE INC. accounted for 58.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Vraylar by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $215.08 | 58.5% | 14 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $80.75 | 21.9% | 3 | 2025 |
| SANOFI PASTEUR INC. | Unresolved — no canonical attribution shown | $28.11 | 7.6% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $27.00 | 7.3% | 1 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $16.91 | 4.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $367.85 | 20 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $215.08 | 14 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $80.75 | 3 | 2025 |
Source payment records
|
|||||
| BEYFORTUS Normalized: beyfortus |
Biological | SANOFI PASTEUR INC. | $28.11 | 1 | 2025 |
Source payment records
|
|||||
| FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE Normalized: flublok quadrivalent northern hemisphere |
Biological | SANOFI PASTEUR INC. | $28.11 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $27.00 | 1 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $16.91 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 33 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 330 | 60 |
| Levothyroxine Sodium | Levothyroxine Sodium | 299 | 50 |
| Omeprazole | Omeprazole | 249 | 50 |
| Gabapentin | Gabapentin | 248 | 57 |
| Atorvastatin Calcium | Atorvastatin Calcium | 230 | 57 |
| Potassium Chloride | Potassium Chloride | 222 | 45 |
| Lisinopril | Lisinopril | 208 | 48 |
| Alprazolam | Alprazolam | 190 | 35 |
| Pantoprazole Sodium | Pantoprazole Sodium | 179 | 38 |
| Furosemide | Furosemide | 176 | 35 |
| Metoprolol Succinate | Metoprolol Succinate | 175 | 29 |
| Carvedilol | Carvedilol | 165 | 35 |
| Zolpidem Tartrate | Zolpidem Tartrate | 156 | 27 |
| Sertraline Hcl | Sertraline Hcl | 141 | 26 |
| Meloxicam | Meloxicam | 138 | 36 |
| Baclofen | Baclofen | 133 | 20 |
| Metformin Hcl | Metformin Hcl | 130 | 32 |
| Amlodipine Besylate | Amlodipine Besylate | 123 | 30 |
| Citalopram Hbr | Citalopram Hydrobromide | 118 | 18 |
| Metoprolol Tartrate | Metoprolol Tartrate | 110 | 20 |
| Duloxetine Hcl | Duloxetine Hcl | 109 | 26 |
| Losartan Potassium | Losartan Potassium | 104 | 23 |
| Fluoxetine Hcl | Fluoxetine Hcl | 97 | 16 |
| Tramadol Hcl | Tramadol Hcl | 97 | 28 |
| Montelukast Sodium | Montelukast Sodium | 95 | 23 |
| Diclofenac Sodium | Diclofenac Sodium | 93 | 20 |
| Azithromycin | Azithromycin | 91 | 61 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 91 | 18 |
| Hydrochlorothiazide | Hydrochlorothiazide | 89 | 23 |
| Quetiapine Fumarate | Quetiapine Fumarate | 84 | 14 |
| Simvastatin | Simvastatin | 84 | 21 |
| Torsemide | Torsemide | 75 | 16 |
| Trazodone Hcl | Trazodone Hcl | 75 | 16 |
| Pregabalin | Pregabalin | 72 | 16 |
| Eliquis | Apixaban | 70 | 13 |
| Celecoxib | Celecoxib | 64 | 15 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 60 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 59 | suppressed |
| Ozempic | Semaglutide | 59 | 17 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 57 | 44 |
| Methylprednisolone | Methylprednisolone | 54 | 42 |
| Tamsulosin Hcl | Tamsulosin Hcl | 52 | 13 |
| Buspirone Hcl | Buspirone Hcl | 50 | suppressed |
| Famotidine | Famotidine | 50 | 12 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 48 | 12 |
| Clopidogrel | Clopidogrel Bisulfate | 47 | 15 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 46 | 17 |
| Farxiga | Dapagliflozin Propanediol | 46 | 11 |
| Jardiance | Empagliflozin | 44 | 12 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 44 | suppressed |
| Aripiprazole | Aripiprazole | 43 | suppressed |
| Clonazepam | Clonazepam | 43 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 42 | 29 |
| Glipizide | Glipizide | 42 | suppressed |
| Gemfibrozil | Gemfibrozil | 41 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 40 | 13 |
| Nifedipine Er | Nifedipine | 40 | suppressed |
| Cephalexin | Cephalexin | 39 | 27 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 39 | suppressed |
| M-Natal Plus | Pnv,calcium 72/Iron/Folic Acid | 37 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 37 | suppressed |
| Sucralfate | Sucralfate | 37 | 12 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 36 | 36 |
| Donepezil Hcl | Donepezil Hcl | 36 | suppressed |
| Allopurinol | Allopurinol | 35 | suppressed |
| Fluconazole | Fluconazole | 35 | 16 |
| Fluticasone Propionate | Fluticasone Propionate | 35 | 12 |
| Prednisone | Prednisone | 35 | 16 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 35 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 34 | suppressed |
| Topiramate | Topiramate | 34 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 33 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 33 | suppressed |
| Vraylar | Cariprazine Hcl | 33 | suppressed |
| Spironolactone | Spironolactone | 32 | 12 |
| Escitalopram Oxalate | Escitalopram Oxalate | 31 | suppressed |
| Lorazepam | Lorazepam | 31 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 30 | suppressed |
| Risperidone | Risperidone | 30 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 30 | 13 |
| Diazepam | Diazepam | 29 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 29 | suppressed |
| Glimepiride | Glimepiride | 27 | suppressed |
| Levofloxacin | Levofloxacin | 27 | 22 |
| Ondansetron Odt | Ondansetron | 27 | 13 |
| Divalproex Sodium Er | Divalproex Sodium | 26 | suppressed |
| Atenolol | Atenolol | 25 | suppressed |
| Valproic Acid | Valproic Acid | 24 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 23 | suppressed |
| Glipizide Er | Glipizide | 22 | suppressed |
| Ramipril | Ramipril | 22 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 22 | suppressed |
| Ibuprofen | Ibuprofen | 21 | suppressed |
| Memantine Hcl | Memantine Hcl | 21 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 21 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 21 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 21 | suppressed |
| Lactulose | Lactulose | 20 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 20 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 20 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 20 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 19 | 13 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 19 | suppressed |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 19 | 17 |
| Nystatin | Nystatin | 19 | 15 |
| Paroxetine Hcl | Paroxetine Hcl | 19 | suppressed |
| Trulicity | Dulaglutide | 19 | suppressed |
| Bupropion Xl | Bupropion Hcl | 18 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 18 | suppressed |
| Acyclovir | Acyclovir | 17 | 12 |
| Doxycycline Hyclate | Doxycycline Hyclate | 17 | suppressed |
| Januvia | Sitagliptin Phosphate | 17 | suppressed |
| Lamotrigine | Lamotrigine | 17 | suppressed |
| Linzess | Linaclotide | 17 | suppressed |
| Methocarbamol | Methocarbamol | 17 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 16 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 16 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 16 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 16 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 16 | 15 |
| Terazosin Hcl | Terazosin Hcl | 16 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 15 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 15 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 15 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 14 | 11 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 14 | suppressed |
| Dutasteride | Dutasteride | 14 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 14 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 13 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 13 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 13 | suppressed |
| Irbesartan | Irbesartan | 13 | suppressed |
| Klor-Con M20 | Potassium Chloride | 13 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 13 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 13 | suppressed |
| Nitroglycerin | Nitroglycerin | 13 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 12 | suppressed |
| Rivastigmine | Rivastigmine | 12 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 12 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 11 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 11 | suppressed |
| Fentanyl | Fentanyl | 11 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 11 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 11 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 11 | suppressed |
| Mirtazapine | Mirtazapine | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | suppressed |
| Sotalol | Sotalol Hcl | 11 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 11 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 11 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $367.85 · 20 records | ABBVIE INC. | BEYFORTUS, FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE, JOURNAVX, REXULTI, The Cologuard Plus Collection Kit, VRAYLAR | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Vraylar play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error